Background/Objectives: A negative association between cigarette smoking and celiac disease has been observed but results were inconsistent across the published studies. A meta-analysis was conducted with the aim to identify all studies that investigated this association and to summarize the results of those studies. Methods: A comprehensive literature review was conducted utilizing MEDLINE and Embase databases through March 2018 to identify all cohort studies and case-control studies that compared the risk of celiac disease among current and/or former smokers versus never-smokers. Effect estimates from each study were extracted and combined together using the randomeffect, generic inverse variance method of DerSimonian and Laird. Results: A total of seven studies with 307,924 participants fulfilled the eligibility criteria and were included in the metaanalysis. The pooled analysis found a significantly decreased risk of celiac disease among current smokers compared with never-smokers with the pooled odds ratio (OR) of 0.52 (95% confidence interval (CI), 0.32-0.84; I 2 86%). However, the risk of celiac disease among former smokers was not significantly different from never-smokers with the pooled OR of 1.10 (95% CI, 0.76-1.60; I 2 of 73%). Conclusions: A significantly decreased risk of celiac disease among current smokers compared with never-smokers was demonstrated in this meta-analysis.
Introduction
Celiac disease or gluten-sensitive enteropathy is a common disease of the gastrointestinal tract with the estimated prevalence in the United States (US) and
Europe of approximately 0.7-1%. 1 Classic clinical manifestations of celiac disease include diarrhea, steatorrhea, flatulence and complications of malabsorption although milder form of the disease, including subclinical disease, is probably even more common and is often not recognized. [2] [3] [4] Cigarette smoking is still a major public health concern in the US that directly and indirectly led to 448,865 deaths in 2014. 5 It is one of the strongest risk factors for several diseases such lung cancer, chronic obstructive pulmonary disease, coronary artery disease and cerebrovascular disease. 6 However, interestingly, studies have suggested that cigarette smoking is associated with a lower risk of some gastrointestinal diseases, including ulcerative colitis, 7, 8 and primary sclerosing cholangitis. 9 A similar negative association between cigarette smoking and celiac disease has been observed as well although the results were inconsistent across the published studies. [10] [11] [12] [13] [14] [15] [16] The current systematic review and meta-analysis was conducted with the aim of identifying all studies that investigated this association and to summarize the results of those studies.
Methods

Information sources and search strategy
A systematic literature search of the MEDLINE and Embase databases was carried out from inception to March 2018 to identify all original studies that investigated the association between cigarette smoking and celiac disease. The systematic literature review was independently conducted by three investigators (K.W., P.P., and P.U.) using a search strategy that included the terms for ''celiac disease'', ''gluten enteropathy'', ''smoking'', ''tobacco'', and ''cigarette'' as described in online supplementary data 1. No language limitation was applied. A hand-search was also performed on references of selected retrieved articles. The meta-analysis was conducted according to the PRISMA (preferred reporting items for systematic reviews and meta-analysis) statement, which is provided as online supplementary data 2.
Selection criteria
Studies that were eligible for this meta-analysis must be either case-control studies or cohort studies that investigated the relationship between smoking status and risk of celiac disease. For case-control studies, cases must be patients with celiac disease, and controls must be individuals without celiac disease. The exposure of interest must be history of cigarette smoking. Since we planned to use never-smokers as the reference group, eligible studies must report the number of current and/or former smokers as well as never smokers for both cases and controls. Alternatively, studies may report odds ratios (ORs) and 95% confidence interval (CIs) of having celiac disease among current and/or former smokers versus never-smokers. For cohort studies, cases must be current and/or former smokers whereas comparators must be never-smokers. One of the outcomes of the study must be the occurrence of celiac disease after the entrance of the cohort for both cases and comparators, which could be reported as relative risk (RR) or hazard ratio (HR) with 95% CI. Inclusion was not limited by study size. When more than one article utilizing the same database/cohort was available, only one study with the most comprehensive data/analyses was included.
Retrieved articles were reviewed for their eligibility independently by the same three investigators (K.W., P.P., and P.U.) with disagreements resolved by consensus. The Newcastle-Ottawa quality assessment scale was used to appraise the quality of the studies in three domains, which included the recruitment of participants, the comparability between the groups, as well as the ascertainment of the outcome of interest for cohort study, and the ascertainment of the exposure of interest for case-control study. 17 
Data abstraction
The investigators used a structured information collection form to extract the following data from each study: title of the study, name of the first author, publication year, year of the study, country where the study was conducted, number of subjects, demographics of subjects, methods used to identify and verify smoking status and celiac disease, adjusted effect estimates with 95% CI, and covariates that were adjusted in the multivariable analysis.
To ensure the accuracy, this data extraction process was independently performed by two investigators (K.W. and P.P.) and was reviewed by the senior investigator (P.U.).
Statistical analysis
Data analysis was performed using the Cochrane Collaboration's Review Manager 5.3 software (London, UK). Adjusted point estimates from each study were consolidated by the generic inverse variance method of DerSimonian and Laird, which assigned the weight of each study for the pooled analysis based on its variance. 18 As the outcome of interest was relatively uncommon, we planned to use the RR and HR of cohort studies as an estimate for the OR to calculate the pooled effect estimates with OR of case-control studies. In light of the high likelihood of high between-study variance because of different study designs, populations, and methodologies, a randomeffect model was used. Cochran's Q test and I 2 statistic were used to quantify the between-study heterogeneity. A value of I 2 of 0-25% represents insignificant heterogeneity, 26-50% represents low heterogeneity, 51-75% represents moderate heterogeneity, and more than 75% represents high heterogeneity. 19 Funnel plot was used to assess for the presence of publication bias. A comprehensive Meta-analysis 3.0 software (Englewood, NJ) was used to perform Egger's regression test for evaluation of publication bias. 20 For all analyses, a P-value less than 0.05 was considered statistically significant.
Results
A total of 569 potentially eligible articles were identified using the described search strategy (195 from Medline and 374 from EMBASE). After the exclusion of 188 duplicated articles, titles and abstracts of 381 unique articles were reviewed. Another 331 articles were excluded at this stage since they were case reports, case series, correspondence, review articles, in vitro studies, animal studies or interventional studies, leaving 50 articles for full-text review. Of these, 16 were excluded after full-length review as they did not report the outcome of interest, while 25 articles were excluded since they were descriptive studies without comparative analysis. A total of nine studies fulfilled the eligibility criteria but four studies utilized the same databases, 14/21;10/22 and only the studies with the most comprehensive data were included. 10, 14 Finally, seven studies with 307,924 participants were included in the meta-analysis. [10] [11] [12] [13] [14] [15] [16] The literature retrieval, review and selection process are shown in Figure 1 . The characteristics and quality appraisal of the included studies are presented in Table 1 . Inter-rater agreement for the quality assessment using the Newcastle-Ottawa scale was high with a kappa statistic of 0.69.
Risk of celiac disease among current smokers
The pooled analysis found a significantly decreased risk of celiac disease among current smokers compared with never-smokers with the pooled OR of 0.52 (95% CI, 0.32-0.84) as demonstrated in Figure 2 . The betweenstudy heterogeneity was high with an I 2 of 86%.
Risk of celiac disease among former smokers
The risk of celiac disease among former smokers was not significantly different from never-smokers with the pooled OR of 1.10 (95% CI, 0.76-1.60) as demonstrated in Figure 3 . The between-study heterogeneity was moderate, with an I 2 of 73%.
Sensitivity analysis
A sensitivity analysis was conducted by including the studies by Thomason et al. 22 and Snook et al. 21 that were excluded because of the concern over potential patient duplication with the studies by Suman et al. 14 and Austin et al. 10 , respectively, instead of those two studies to investigate if the decision to include one of the two studies with potential overlap had a significant effect on the outcomes of this meta-analysis. We found that the outcomes of this sensitivity analysis were similar to the original analysis that a significantly decreased risk of celiac disease among current smokers compared with never-smokers was observed (pooled OR 0.46, 95% CI 0.26-0.81, I
2 87%) whereas the risk of celiac disease among former smokers was not significantly different from never-smokers (pooled OR 1.12, 95% CI 0.76-1.66, I 2 68%).
Evaluation for publication bias
A funnel plot was constructed based on effect estimate and accuracy of each study to assess for the presence of publication bias. The funnel plots for current smokers versus never-smokers analysis and former smokers versus never-smokers analysis are shown as Figures 4 and 5, respectively. Both funnel plots were relatively symmetric and, therefore, were not suggestive of the presence of publication bias. In addition, there was no evidence of publication bias by Egger's regression test with the p-value of 0.13 and 0.35 for current smokers versus never-smokers analysis and former smokers versus never-smokers analysis, respectively.
Discussion
The current study is the first systematic review and meta-analysis to summarize all available studies on the risk of celiac disease among smokers. The pooled analysis found an almost 50% decreased risk of celiac disease among current smokers compared with neversmokers. However, a similar risk reduction was not observed among former smokers. This observation may suggest that cigarette smoking could be a protective environmental factor against the development of celiac disease although the effect appears to attenuate after smoking cessation. The reasons as to why cigarette smoking may decrease the risk of celiac disease is not well understood but there are few possible explanations. 23 The first explanation is based on the immunomodulatory effects of cigarette smoking on both cellular and humoral immune function. 24, 25 Since activation of T cells in the gut mucosa by gliadin is the pivotal step in the pathogenesis of the mucosal inflammation of celiac disease, 2 26,27 it is possible that smoking may alter the capacity of T cells to respond to gliadin and, thus, lower the chance of development of celiac disease. Some studies also suggested that cigarette smoking may decrease the expression of tissue transglutaminase enzyme, 28, 29 an enzyme that plays an important role in the amplification of response of T cells to gliadin through conversion of glutamine residues into glutamic acid, which creates deamidated gluten peptides that can bind efficiently to human leukocyte antigen (HLA)-DQ2/-DQ8 presented on antigen-presenting cells. 30 The second explanation is related to the fact that cigarette smoking has been shown to reduce gut permeability. 31 As epithelial barrier impairment resulting in increased gut permeability of immunogenic gluten peptides is considered one of the early events in the pathogenesis of celiac disease, 30 smoking may help lowering the risk of celiac disease by decreasing the permeability of the gut.
Although the literature review was comprehensive, and the included studies were of high quality as reflected by the quality assessment scores, we acknowledge that the current study has some limitations.
First, between-study statistical heterogeneity was not low in both analyses. We suspect that the differences in 16 Todi et al. 11 Patel et al. 13 Vazquez et al. the study populations, designs, and methodologies were responsible for the variation. Second, confounders may play a role in this meta-analysis as it is a meta-analysis of observational studies and most of the included studies did not adjust their effect estimates for potential confounders (except for age and sex). Third, almost all of the included studies were conducted in the US and Europe. Therefore, generalizability of the results to other regions around the globe could be limited. In summary, this systematic review and meta-analysis found a significantly decreased risk of celiac disease among current smokers compared with never-smokers. However, a similar risk reduction was not observed among former smokers. 
